Article

Urology Times, Digital Edition, July 2010

Related Videos
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
1 expert in this video
Using Ultrasensitive PSA Assays in Routine Practice
1 expert in this video
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
1 expert is featured in this series.
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
2 experts are featured in this series.
Key Benefits of PET in ccRCC Risk Stratification
4 experts in this video
Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
2 experts are featured in this series.
Early Detection of ccRCC
1 expert is featured in this series.
Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Related Content
Zanzalintinib plus nivolumab shows promising clinical activity in ccRCC
June 4th 2025

Zanzalintinib plus nivolumab shows promising clinical activity in ccRCC

Hannah Clarke
According to the authors, these data support the ongoing investigation of zanzalintinib in combination with immune checkpoint inhibitors.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Adding niraparib to AAP extends rPFS in HRR-positive mCSPC
June 4th 2025

Adding niraparib to AAP extends rPFS in HRR-positive mCSPC

Hannah Clarke
“AMPLITUDE supports early genomic testing and niraparib plus AAP as a new treatment option for patients with mCSPC and HRR gene alterations," the authors wrote.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Rana R. McKay, MD, FASCO
June 4th 2025

COMRADE: Olaparib plus radium-223 improves rPFS in mCRPC

Benjamin P. Saylor
“This was a positive study, resulting in a statistically significant improvement in the primary end point of rPFS in the intent-to-treat population," said Rana R. McKay, MD, FASCO.
FDA approves darolutamide in metastatic castration-sensitive prostate cancer
June 3rd 2025

FDA approves darolutamide in metastatic castration-sensitive prostate cancer

Hannah Clarke
The approval is supported by data from the pivotal phase 3 ARANOTE trial.
© 2025 MJH Life Sciences

All rights reserved.